SOX11 is a transcriptional circuit dosage sensitive transcription factor controlling SWI/SNF components

Moritz Gartlgruber , Wouter Van Loocke , Jo Van Dorpe , Franki Speleman
Advances in Neuroblastoma Research, Congress abstracts

2018
TBX2 is implicated in cell cycle control and proliferation in neuroblastoma

Gudrun Schleiermacher , Moritz Gartlgruber , Valentina Boeva , Daniel Dreidax
18th Annual BeSHG meeting: The epigenome in development and disease

2018
Così vissi il tramonto dell'era Ceausescu

Frank Westerman , Cristina Vezzaro
LA REPUBLICCA 38 -39

2019
Inferring a tumor progression model for neuroblastoma from genomic data

Sven Bilke , Qing-Rong Chen , Frank Westerman , Manfred Schwab
J Clin Oncol 23 ( 29) 7322 -31

54
2005
The core regulatory circuit component TBX2 is implicated in cell cycle control and proliferation in neuroblastoma

Bieke Decaesteker , Geertrui Denecker , Wouter Van Loocke , Moritz Gartlgruber
7th Villa Joep Scientific progress meeting

2017
TUMOR BIOLOGY OF ADULT AND PEDIATRIC MEDULLOBLASTOMAS REQUIRES DISTINCT APPROACHES FOR MOLECULAR RISK STRATIFICATION

M Remke , A Korshunov , PA Northcott , W Werft
NEURO-ONCOLOGY 12 ( 6) II57 -II57

2010
Histone Deacetylase 8i n NeuroblastomaTumorigenesis

Andreas von Deimling , Annette Kopp-Schneider , Barbara Hero , Frank Westermann

418
2009
MYCN directly regulates long non-coding RNA expression in neuroblastoma

Frank Westermann , Johannes Schulte , Jo Vandesompele , Franki Speleman
Advances in Neuroblastoma Research 2012 (ANR 2012)

2012
HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Tom Van Maerken , Frank Westermann , Johannes Schulte , Laurel Bate-Eya
Opening symposium for the new Treatment and Research Center for Pediatric Oncology and Haematology Heidelberg

2017
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Tom Van Maerken , Frank Westermann , Johannes Schulte , Laurel Bate-Eya
Annual meeting of the American Association for Cancer Research (AACR) 2017 58 1484 -1484

2017
BRD3 as a specific vulnerable therapeutic target in neuroblastoma

Kaat Durinck , Frank Westermann , Anneleen Beckers , Franki Speleman
Protecting the Code : Epigenetic Impacts on Genome Stability, EACR conference, Abstracts

2017
SOX11 as mediator of the adrenergic cell state in NB

Kaat Durinck , Moritz Gartlgruber , Frank Westermann , Wouter Van Loocke
Pediatric Oncology and Hematology, 2nd KiTZ symposium, Abstracts

2019
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.

Barbara Hero , Moritz Gartlgruber , Frank Westermann , Matthias Selbach
Nature Communications 12 ( 1) 1 -18

35
2021
Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma.

Moritz Gartlgruber , Daniel Dreidax , Vitaliya Sagulenko , Frank Westermann
Life Science Alliance 4 ( 5)

2021
Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma.

Selina Jansky , Ashwini Kumar Sharma , Verena Körber , Andrés Quintero
Nature Genetics 53 ( 5) 683 -693

82
2021
SOX11 as guardian of epigenetic plasticity in neuroblastoma

Kaat Durinck , Frank Westermann , Wouter Van Loocke , Johannes Schulte
Advances in Neuroblastoma Research (ANR 2021), Abstracts

2021
Ataxin-2 promotes apoptosis of human neuroblastoma cells

Ruprecht Wiedemeyer , Frank Westermann , Isabel Wittke , Joachim Nowock
Oncogene 22 ( 3) 401 -411

52
2003
Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification

André Oberthuer , Frank Berthold , Patrick Warnat , Barbara Hero
Journal of Clinical Oncology 24 ( 31) 5070 -5078

234
2006
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts.

Jagoda K Wrobel , Sara Najafi , Simay Ayhan , Charlotte Gatzweiler
Pharmaceuticals, policy and law 13 ( 11) 345

2
2020